Maxygen, Inc. (NASDAQ: MAXY)

Maxygen, Inc. (NASDAQ: MAXY) was founded with the purpose of developing important commercial products by leveraging biotechnology. Since then, the company has established a pipeline of product candidates that address unmet medical needs. Maxygen’s key protein pharmaceutical programs include: MAXY-G34 , an improved G-CSF protein to treat neutropenia; MAXY-VII , an improved factor VIIa protein to treat hemophilia; and MAXY-4 , an improved CTLA4-Ig protein to treat rheumatoid arthritis. For further information, visit the Company’s web site at www.maxygen.com.